Clinical trials: Essential Hypertension
Essential Hypertension
A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers
The purpose of this study is to evaluate the effect of atorvastatin on the pharmacokinetics of fimasartan.
- Trial name
- NCT00991705
- Testing
- Atorvastatin, Fimasartan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Micardis® in Patients With Essential Hypertension
The aim of this observational study was to supplement the data on efficacy, safety, and tolerability of telmisartan under daily conditions in hospitals
- Trial name
- NCT02187705
- Testing
- Telmisartan tablets
- Volunteers
- 1,688 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy
The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor…
- Trial name
- NCT00144222
- Testing
- Telmisartan 40 mg/HCTZ 12.5 mg, Telmisartan 40 mg
- Where
- 2 sites in Japan
- Volunteers
- 218 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Cardiovascular Diseases
Global Paradise System US Post Approval Study
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood…
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- US GPS (NCT06297291)
- Testing
- Paradise Ultrasound Renal Denervation Treatment
- Where
- 46 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- ReCor Medical, Inc.
Essential Hypertension
A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) during 24 hours by dose in patients with mild to moderate essential hypertension.
- Trial name
- NCT00922441
- Testing
- Fimasartan 60 mg group, Fimasartan 120 mg group, Reference (Valsartan 80 mg) group
- Volunteers
- 92 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Essential Hypertension
Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients with Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy
- Trial name
- NCT06682000
- Testing
- DWC202404, DWC202314, DWC202404, DWC202314P
- Where
- South Korea
- Volunteers
- 192 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-2 and RLD2001-2 alone in patients with essential hypertension inadequately controlled on RLD2001-2 monotherapy.
- Trial name
- NCT04830449
- Testing
- HCP1904-2, RLD2001-2
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine
The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Amlodipine (5mg).
- Trial name
- NCT07704684
- Testing
- Experimental: Sacubitril/Allisartan and Amlodipine Group, Active Comparator: Amlodipine Group
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Essential Hypertension
Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects
1QG2 is a Phase 1 study aiming to assess the safety and tolerability of ascending single/multiple oral doses (SAD \& MAD) in healthy young subjects, the preliminary food interaction and the effect of QGC001 on blood pressure and…
- Trial name
- NCT01900184
- Testing
- QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
- Where
- France
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Quantum Genomics SA
Hypertension
Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension
This will be a multi-center, prospective, randomized, open-label, parallel design, two arm comparator trial. In the proposed study, the investigators will compare low-dose combination therapy of Nifedipine GITS/OROS plus…
- Trial name
- NCT00993109
- Testing
- Adalat (Nifedipine, BAYA1040), Diovan (Valsartan)
- Where
- 17 sites in China, South Korea
- Volunteers
- 360 people
- Sponsor
- Bayer
Essential Hypertension
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Perindopril Erbumine 8 mg tablets under fasting conditions.
- Trial name
- NCT01012687
- Testing
- perindopril erbumine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Hypertension
Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension
The aim of present study is to evaluate the efficacy and safety of Carvedilol SR versus Carvedilol IR in Patients With Essential Hypertension
- Trial name
- NCT01756430
- Testing
- Carvedilol SR 32mg, QD, Carvedilol SR 64mg, QD, Carvedilol IR 25mg, QD
- Where
- South Korea
- Volunteers
- 238 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension
This study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination.
- Trial name
- NCT06282549
- Testing
- Telmisartan/Amlodipine/Chlorthalidone(Truset)
- Where
- 5 sites in South Korea
- Volunteers
- 1,219 people
- Sponsor
- Yuhan Corporation
Hypertension
TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch
The general aim of this trial to determine the efficacy as measured by the percentage of patients reaching blood pressure goal at the end of the treatment period at 12 weeks.
- Trial name
- NCT01134393
- Testing
- telmisartan/amlodipine
- Where
- 47 sites in Germany, Italy and 3 more
- Volunteers
- 502 people
- Sponsor
- Boehringer Ingelheim
Hypertension
A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure
Carvedilol controlled release is a marketed drug to treat high blood pressure. This study is to compare carvedilol controlled release to carvedilol controlled release plus lisinopril (fixed-dose combination) after repeat dosing…
- Trial name
- NCT00537043
- Testing
- SK&F-105517 (COREG CR FDC)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Essential Hypertension
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.
- Trial name
- NCT01289132
- Testing
- Azilsartan, Candesartan cilexetil
- Volunteers
- 926 people
- Sponsor
- Takeda
Uncomplicated Hypertension, Hypertension
The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients
The sustained reduction in elevated blood pressure and lower incidence of adverse events of Lacidipine may provide additional benefits for hypertension patients than other CCBs (calcium channel blockers).
- Conditions
- Uncomplicated Hypertension, Hypertension, Essential
- Trial name
- NCT00338338
- Testing
- Lacidipine 4 or 6 mg (oral), Amlodipine 5 or 10 mg(oral)
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline